Ignite Creation Date:
2025-12-25 @ 2:15 AM
Ignite Modification Date:
2026-04-15 @ 11:11 PM
Study NCT ID:
NCT02397460
Status:
COMPLETED
Last Update Posted:
2021-02-12
First Post:
2015-03-09
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
Sponsor:
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-04-29
Start Date Type:
ACTUAL
Primary Completion Date:
2016-04-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-05-16
Completion Date Type:
ACTUAL
First Submit Date:
2015-03-09
First Submit QC Date:
None
Study First Post Date:
2015-03-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-01-26
Results First Submit QC Date:
None
Results First Post Date:
2021-02-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-01-26
Last Update Post Date:
2021-02-12
Last Update Post Date Type:
ACTUAL